Drug General Information |
Drug ID |
D0V7RM
|
Former ID |
DNC014042
|
Drug Name |
(6-Butoxy-2-naphthyl)-2-aminopropane
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H23NO
|
Canonical SMILES |
CCCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
|
InChI |
1S/C17H23NO/c1-3-4-9-19-17-8-7-15-11-14(10-13(2)18)5-6-16(15)12-17/h5-8,11-13H,3-4,9-10,18H2,1-2H3
|
InChIKey |
HQJXBGMWVQCDJS-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
Dopamine degradation
|
Putrescine degradation III
|
Noradrenaline and adrenaline degradation
|
Serotonin degradation
|
Superpathway of melatonin degradation
|
Melatonin degradation II
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
Arginine and proline metabolism
|
Histidine metabolism
|
Tyrosine metabolism
|
Phenylalanine metabolism
|
Tryptophan metabolism
|
Drug metabolism - cytochrome P450
|
Metabolic pathways
|
Serotonergic synapse
|
Dopaminergic synapse
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholism
|
NetPath Pathway
|
IL4 Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
5-Hydroxytryptamine degredation
|
Dopamine receptor mediated signaling pathway
|
PathWhiz Pathway
|
Histidine Metabolism
|
Tyrosine Metabolism
|
Glycine and Serine Metabolism
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Biogenic Amine Synthesis
|
Oxidative Stress
|
Dopamine metabolism
|
Phase 1 - Functionalization of compounds
|
Neurotransmitter Release Cycle
|
Neurotransmitter Clearance In The Synaptic Cleft
|
Serotonin Transporter Activity
|
References |
REF 1 | Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. Epub 2009 Feb 8.Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. |